Core Viewpoint - A-shares have lower trading costs and better market liquidity compared to H-shares, with a current premium of about 20% for A-shares as indicated by the Hang Seng AH Premium Index (HSAHP) being above 120. However, certain companies like CATL have shown a reverse phenomenon where H-shares are priced higher than A-shares [2][4]. Group 1: Market Dynamics - The phenomenon of H-shares trading at a premium over A-shares is attributed to the smaller market capitalization of H-shares compared to A-shares, leading to relative scarcity in liquidity [5]. - Among the six companies exhibiting this "inversion," three are newly listed, resulting in lower liquidity for H-shares, which can lead to inflated prices due to concentrated holdings by large institutions [5][6]. - As institutional investors gradually exit their positions, the liquidity of H-shares is expected to increase, potentially narrowing the premium of H-shares over A-shares [5]. Group 2: Characteristics of A-H Share Companies - Companies with inverted pricing typically share common traits: they are large enterprises with stable operating histories and solid financials, often in traditional industries like finance and energy [6]. - The valuation of these companies tends to be higher in the A-share market, reflecting differing expectations from overseas investors regarding future growth potential [6][8]. Group 3: Foreign Investment Preferences - Foreign investors prefer industry leaders that have a competitive edge in the market, which are often scarce in the international market [8]. - These leading companies usually possess strong brand recognition, stable profitability, and good governance structures, aligning with foreign investors' long-term investment criteria [8][9]. - The preference for H-shares over A-shares is also influenced by the perceived monopolistic characteristics of certain companies, which can lead to higher valuations in the H-share market [9].

Core Viewpoint - The phenomenon of "AH share premium inversion" is observed in six companies, where H-shares are priced higher than A-shares, attributed to low liquidity and foreign investors' preference for industry leaders [1][2]. Group 1: Market Dynamics - The Heng Seng AH Share Premium Index (HSAHP) remains above 120, indicating a 20% premium of A-shares over H-shares [1]. - The six companies experiencing this inversion include CATL, China Merchants Bank, Hengrui Medicine, Weichai Power, WuXi AppTec, and Midea Group [2]. - The market sees a preference for newly listed stocks in the H-share market, which have lower liquidity, leading to higher valuations [2]. Group 2: Liquidity and New Listings - The "inversion" stocks are characterized by a high proportion of newly listed shares, with three of the six companies listed for less than a year [2]. - The market capitalization of H-shares is often significantly smaller than that of A-shares, contributing to the liquidity scarcity and price inversion [2]. - As institutional investors gradually exit their IPO allocations, the liquidity in the H-share market is expected to increase, potentially narrowing the premium [2]. Group 3: Foreign Investment Preferences - Foreign investors show a strong preference for industry leaders that have established market positions and stable financials [3][4]. - These companies typically operate in traditional sectors such as finance, energy, and infrastructure, which have predictable profit models [3]. - The preference for H-shares is also driven by the perception of higher growth potential and better governance structures in these companies [4]. Group 4: Examples of Inversion - BYD and China Merchants Bank are highlighted as typical examples of companies where H-shares occasionally exhibit a premium over A-shares [5]. - The presence of monopolistic characteristics in H-shares can attract foreign investment, as these companies are often seen as irreplaceable in the global market [5].

近期，药明康德持续受到资本市场关注，一系列股东减持与资产优化举措引发了市场讨论。然而，深入 分析其战略逻辑与行业地位不难发现，公司长期价值根基依然稳固，投资者对其未来发展的信心并未动 摇。 10月29日，药明康德发布公告称，17家股东因自身资金需求计划减持不超过公司总股本2%的A股股 份，比例可控。随后在11月26日，公司进一步披露了阶段性减持进展：2025年11月20日至25日期间，相 关股东合计减持1182.79万股，占总股本的0.3963%。值得关注的是，在此期间公司股价逆势上涨 1.19%，截至11月25日收盘报94.31元。这一市场表现表明，尽管面临股东减持带来的情绪波动，更多投 资者仍看好公司的长期发展前景。 股东减持作为资本市场中的常见行为，应在合理监管框架下理性看待。对药明康德这类已步入成熟发展 阶段的规模化企业而言，股东适度减持多属于正常的资产配置调整。从药明康德此次减持计划的披露情 况来看，整个过程符合监管要求，规范且透明。 另外，公告也指出，大宗交易的买方在受让后6个月内不得转让，这种"锁定期"约束也能降低二级市场 快速抛售的风险，确保减持节奏温和可控，压抑缓解冲击。 自2018年实现" ...

Core Insights - A-shares have lower trading costs and better market liquidity compared to H-shares, with a current premium of approximately 20% for A-shares as indicated by the Hang Seng AH Premium Index (HSAHP) being above 120 [1][2] - A peculiar situation has arisen where H-shares of certain companies, such as CATL, are trading at higher prices than their A-shares, attributed to factors like limited liquidity and the preference of overseas investors for industry leaders [1][2][3] Group 1: Market Dynamics - The six companies experiencing H-share price premiums over A-shares include CATL, China Merchants Bank, Hengrui Medicine, Weichai Power, WuXi AppTec, and Midea Group [2] - The phenomenon of H-share price premiums is linked to the smaller market capitalization of H-shares compared to A-shares, leading to relative scarcity in liquidity [2][3] - Newly listed companies in the H-share market tend to have lower trading volumes, which can lead to inflated prices due to concentrated holdings by large institutions [2][3] Group 2: Investor Preferences - Foreign investors show a preference for industry leaders that have established market positions and stable financials, often leading to higher valuations in the H-share market [4][5] - Companies with strong brand recognition and stable profitability are more likely to attract foreign investment, as these factors align with the long-term investment strategies of international investors [4][5] - The preference for H-shares over A-shares is also influenced by the perceived growth potential and governance standards of the companies involved [4][5] Group 3: Specific Company Examples - CATL's H-shares were observed to have a premium of over 30% shortly after listing, which has since narrowed to approximately 13% as liquidity increased [2] - Other examples of companies with close pricing between H-shares and A-shares include BYD and China Merchants Bank, reflecting positive market sentiment regarding their growth prospects and governance [5]

Core Insights - A-shares have lower trading costs and better market liquidity compared to H-shares, with an overall premium of 20% for A-shares as indicated by the Hang Seng AH Premium Index (HSAHP) remaining above 120 [1][2] - A peculiar situation has arisen where H-shares of certain companies, such as CATL, are trading at higher prices than their A-shares, attributed to factors like limited liquidity and the preference of overseas investors for industry leaders [1][2][3] Group 1: Market Dynamics - The six companies experiencing H-share price premiums over A-shares include CATL, China Merchants Bank, Hengrui Medicine, Weichai Power, WuXi AppTec, and Midea Group, with others like Zijin Mining and BYD showing closer price alignment [2][3] - The phenomenon of "inverted pricing" is largely due to the smaller market capitalization of H-shares compared to A-shares, leading to relative scarcity in liquidity which drives up prices [2][3] Group 2: Investor Preferences - Foreign investors show a strong preference for industry leaders that are scarce in the international market, often leading to higher valuations for these companies in H-shares [4][5] - Companies with stable financials and established operational histories, particularly in traditional sectors like finance and energy, tend to attract more foreign investment, reflecting differing growth expectations between domestic and international investors [3][4] Group 3: Future Outlook - As large institutional investors gradually exit their positions, the liquidity of H-shares is expected to increase, potentially narrowing the premium of H-shares over A-shares [2][4] - The case of CATL illustrates this trend, where its H-share premium over A-shares decreased from over 30% to approximately 13% following the unlocking of shares held by certain investors [2][4]

Core Viewpoint - The investment philosophy of Duan Yongping emphasizes understanding the intrinsic value of a company beyond market fluctuations, as illustrated by the recent share reduction news from WuXi AppTec [1] Group 1: Shareholder Actions - On October 29, WuXi AppTec announced a plan for its actual controller to reduce shares by up to 2% of the total share capital through centralized bidding and/or block trading [1] - The market reacted strongly to the news, despite the reduction being relatively small and regulated, indicating a growing desensitization among investors regarding the negative perception of share reductions [1] Group 2: Company Performance - Since October 30, WuXi AppTec's stock has outperformed the market, even increasing by 1.19% during the share reduction period from November 20 to 25 [2] - WuXi AppTec has established a unique business model since its founding in 2000, focusing on assisting pharmaceutical companies in lowering development barriers and accelerating new drug launches [2] Group 3: Financial Metrics - Investors who held WuXi AppTec shares since its IPO have seen a return of 12.3 times by September this year, supported by a solid business model [3] - As of the first half of this year, WuXi AppTec's ongoing business orders have achieved a compound growth rate of 38% since 2018, nearing 60 billion [3] - By the third quarter of 2025, WuXi AppTec's revenue is projected to exceed 32.857 billion, with a year-on-year growth of 18.61% and an increase in net profit margin from 26.5% to 32.1% [3] Group 4: Shareholder Returns - WuXi AppTec's expected earnings per share in 2025 will be seven times that of its IPO, with a total of 20 billion allocated for cash dividends and share buybacks over the past seven years [4] - The company has implemented a nearly 7 billion shareholder return plan for 2025, which represents 72% of the net profit for 2024 [4] - For the first three quarters of 2025, WuXi AppTec's net profit attributable to shareholders reached 12.076 billion, reflecting an 84.84% year-on-year increase [4] Group 5: Long-term Belief - Achieving a 12-fold return over seven years requires a strong belief in the long-term value of the company and the power of belief itself [5]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of December 1, with Northeast Electric (00042) leading with a premium rate of 881.82% [1] - The article also lists the stocks with the highest and lowest deviation values, indicating significant discrepancies between their A-shares and H-shares [1] Summary of Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 881.82%, followed by Hongye Futures (03678) at 274.55% and Sinopec Oilfield Service (01033) at 269.74% [1] - The top ten stocks with high premium rates include Zhejiang Shibao (01057) at 261.98% and Chenming Paper (01812) at 245.83% [1] Summary of Bottom AH Premium Rates - The stocks with the lowest AH premium rates include Ningde Times (03750) at -5.03%, China Merchants Bank (03968) at -1.36%, and Heng Rui Medicine (01276) at 1.50% [1] - Other notable mentions in the bottom list include Weichai Power (02338) at 6.45% and Midea Group (00300) at 7.66% [1] Summary of Deviation Values - The stocks with the highest deviation values are Guanghe Communication (00638) at 31.56%, Dazhong Public Utilities (01635) at 23.38%, and Beijing Jingcheng Machinery Electric (00187) at 20.11% [1] - Conversely, the stocks with the lowest deviation values include Jiangsu Ninghu Expressway (00177) at -13.73%, Junsheng Electronics (00699) at -12.81%, and China Life (02628) at -11.45% [1]

Investment Summary - The innovative pharmaceutical sector is entering a commercialization harvest period, with significant performance improvements in the first three quarters of 2025 [5] - The medical device bidding market shows a substantial growth trend, with a 62.75% year-on-year increase in the first half of 2025 [22] - The rise of health-conscious consumer behavior is driving rapid market growth and innovation in health consumption [5] - Supportive policies from the government are catalyzing high-quality development in the pharmaceutical industry [5] Sector Performance Review - As of November 27, 2025, the pharmaceutical and biotechnology sector has seen a 16.56% increase since the beginning of the year, outperforming the CSI 300 index by 1.81 percentage points [8] - The chemical pharmaceutical sub-sector led the gains with a 33.67% increase, while the medical services and biological products sectors also performed well [8][12] Innovative Pharmaceuticals - Policy support is enhancing the entire chain of high-quality development, with significant improvements in the approval process for innovative drugs [15] - The number of approved innovative drugs has surged, with 48 new first-class innovative drugs approved in 2024, a fivefold increase compared to 2018 [15] - The domestic innovative drug market is expanding rapidly, with a projected market size of 1 trillion yuan by 2035 [21] Medical Insurance Market - The commercial insurance system is gradually improving, with multi-channel payment mechanisms being explored to meet public demand [5] - The aging population is increasing demand in chronic disease and rehabilitation sectors, with over 310 million people aged 60 and above in China by 2024 [5] Medical Devices - The medical device bidding market is recovering, with a 29.8% year-on-year growth in the third quarter of 2025 [22] - The overall revenue for the medical device sector in Q3 2025 was 604.49 billion yuan, showing a positive growth trend [22] Brain-Computer Interface - The brain-computer interface industry is expected to see significant growth, with potential market sizes ranging from 400 to 1450 billion USD by 2030-2040 [23] - National and local policies are promoting innovation in the brain-computer interface sector, with plans to establish several influential enterprises by 2030 [23][25] AI in Healthcare - The AI+ healthcare market is rapidly expanding, with a projected market size of 315.8 billion yuan by 2033, reflecting a compound annual growth rate of 43% [27] - The AI pharmaceutical sector is also growing, with a market size increase from 0.7 million yuan in 2019 to 4.1 million yuan in 2023 [31] Traditional Chinese Medicine - The traditional Chinese medicine sector is experiencing revitalization through new consumption patterns, with a significant increase in the number of TCM clinics across the country [33] - The market for chronic disease management is expanding, with a projected size of 4 trillion yuan by 2024 [33] New Health Consumption - Policies promoting health consumption are driving rapid growth in the health consumption sector, with the total revenue of China's health industry reaching 9 trillion yuan in 2024 [34] - The health consumption market is characterized by rapid growth and continuous innovation in business models [34]

Market Overview - The Hang Seng Index closed at 25,946, up 0.07% for the day and 29.34% year-to-date[4] - The Nikkei 225 index rose 1.23%, driven by strong performance in technology stocks, with a year-to-date increase of 25.75%[11] - The S&P 500 remained unchanged, with a year-to-date gain of 15.83%[4] Sector Performance - Toy and leisure products led the gains in Hong Kong, with companies like Brio and Pop Mart rising over 6%[10] - Consumer electronics stocks also performed well, with TCL Electronics increasing by over 6%[10] - New energy vehicle stocks saw significant gains, with companies like Leap Motor and Chery Auto rising over 4%[10] Economic Indicators - China's industrial enterprises reported a total profit of 59,502.9 billion yuan, a year-on-year increase of 1.9%[15] - The automotive industry produced 27.33 million vehicles from January to October, reflecting an 11% year-on-year growth[15] - The profit margin in the automotive sector was reported at 4.4%, lower than the average of 6% for downstream industrial enterprises[16] Global Developments - President Putin expressed a willingness to negotiate peace regarding the Ukraine conflict, indicating potential future agreements[15] - The European Central Bank's October meeting revealed a consensus on maintaining the current 2% interest rate, though there were differing opinions on the need for further cuts[15] - Morgan Stanley forecasts that emerging markets will continue to rise, with expected returns of around 8% by mid-2026[15]

Core Viewpoint - Nomura's report indicates that WuXi AppTec's strong R&D capabilities enable it to seize market opportunities, reaffirming a "Buy" rating and raising the target price from HKD 130.63 to HKD 132.8 [1] Group 1: Company Performance - As of the end of fiscal year 2025 (September), the company has undertaken a total of 3,430 projects, which is approximately three times the number in 2021 [1] - The breakdown of projects includes 2,889 in preclinical, 374 in Phase I, 87 in Phase II, 80 in Phase III, and commercial stages [1] - The total order backlog reached CNY 59.88 billion, with new orders signed in the third quarter increasing by 32% year-on-year to CNY 15.3 billion [1]